Table 1 Demographic information, previous medications, and major outcomes for all patients
Patient | Age | Sex | Duration of LN (years) | LN class | Previous medications and outcome | Baseline TPU (g/24 h) | Baseline prednisone (mg/d) | Baseline creatine (μmol/L) | Outcome of iguratimod treatment | Follow-up time (weeks) | Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 30 | F | 13 | IV → III§ | Cyc → Cs* (CR → F) | 5.17 | 15 | 43 | PR | 36 | Discontinue (relapse) |
Cyc → LEF* (CR → F) | |||||||||||
RTX (NR) | |||||||||||
2 | 45 | F | 12 | III | Pulse steroids (CR → F) | 1.34 | 5 | 39 | CR | 84 | Follow-up |
Cyc (PR → F) | |||||||||||
MMF (NR) | |||||||||||
TAC (NR) | |||||||||||
3 | 18 | F | 6 | III + V | MMF (PR → F) | 2.33 | 10 | 75.5 | PR | 132 | Follow-up |
TAC (PR → F) | |||||||||||
4 | 49 | F | 7 | III + V | Cyc → MMF* (CR → F) | 4.92 | 0 | 63 | PR | 12 | Discontinue (SAE) |
TAC (NR) | |||||||||||
5 | 55 | F | 18 | III + V | CYC (CR → AE) | 3.33 | 10 | 77 | CR | 132 | Follow-up |
LEF (NR) | |||||||||||
Cyc (NR) | |||||||||||
MMF (PR → F) | |||||||||||
TAC (PR → F) | |||||||||||
6 | 29 | F | 6 | IV + V | TAC (NR) | 3.48 | 0 | 35 | CR | 118 | Follow-up |
MMF (PR → F) | |||||||||||
7 | 30 | F | 23 | IV | Cyc (CR → F) | 6.01 | 15 | 72 | PR | 24 | Discontinue (relapse) |
MMF (PR → F) | |||||||||||
Cs (NR) | |||||||||||
LEF (NR) | |||||||||||
8 | 31 | F | 5 | III + VI → IV + V§ | Cyc → MMF* (PR → F) | 1.96 | 10 | 52 | NR | 28 | NR |
TAC (NR) | |||||||||||
9 | 32 | F | 5 | III + V | Cyc (NR) | 6.01 | 35 | 155 | CR | 36 | Discontinue (extra-renal relapse) |
MMF (NR) | |||||||||||
Sirolimius (NR) | |||||||||||
10 | 26 | F | 4 | III → V§ | Cyc (NR) | 13.79 | 0 | 105 | Lost | 4 | Lost to follow-up |
Cs (NR) | |||||||||||
TAC (NR) | |||||||||||
11 | 46 | M | 6 | III | Cyc (PR → F) | 6.24 | 10 | 72 | PR | 16 | Follow-up |
MMF (PR → F) | |||||||||||
12 | 19 | F | 2 | IV + V | LEF (NR) | 1.32 | 0 | 40.2 | PR | 36 | Discontinue (relapse) |
MMF (PR → F) | |||||||||||
13 | 24 | M | 10 | III + V | Cyc (NR) | 2.21 | 0 | 81 | PR | 32 | Follow-up |
Cs (NR) | |||||||||||
MMF (NR) | |||||||||||
TAC (NR) | |||||||||||
LEF + Tripterygium (NR) | |||||||||||
Cyc (NR) | |||||||||||
14 | 34 | F | 6 | IV | Cyc → LEF* (CR → F) | 2.57 | 10 | 43 | CR | 36 | Follow-up |
Cs (CR → F) | |||||||||||
MMF (NR) | |||||||||||
TAC (NR) | |||||||||||
AZA (NR) |